NCT02886039

Brief Summary

Cardiac arrest (CA) is a major public health problem (1) because of its frequency (30000 to 50000 new cases of CA per year in France), a high mortality 80-90% and a relevant morbidity : 50% of survivors have cerebral sequela. Neurologic prognostication after CA is paramount. The American Academy of Neurology identifies accurate predictors of poor neurologic outcome (2): clinical examination findings such as no pupil response, no corneal reflexes, no motor response to stimulation and early myoclonus status epilepticus; biologic parameters like high neuron specific enolase (NSE) greater than 33 μg/L (3-4) and electrophysiologic results like flat electroencephalogram (EEG) or with burst suppression and Somatosensory evoked potentials (SEP) with no response to N20. Brain imaging may provide additional informations but not recommended yet. However, these pronotic markers were developed before the introduction therapeutic hypothermia (TH) (5-6). TH is now recommended after cardiac arrest by international guidelines, based on demonstration of improved survival and neurological recovery in comatose survivors of CA (7). TH and its associated use of sedative and paralytic agent may delay neurologic recovery and affect the optimal timing of prognostic variables (8). Many classifications of electroencephalogram (EEG) (9-12) exist but no one is generally accept and recommended and they were created before TH. In a preliminary study based on a retrospective cohort of 64 patients in CA with initial TH, we developped an electroencephalographic score to predict precocity the neurologic outcome according to the Cerebral performance category (CPC) (13-14). The purpose of this study is to evaluate a simple and objective electroencephalographic score helpful to predict neurologic outcome after CA. Then, we would like to create a composite score to have a multimodal prognostication. Patients and methods After CA resuscitation, all patients underwent coronary angioplasty if indicated and then were immediately admitted in emergency room of ICU. All patients were intubated and mechanically ventilated. Sedation was performed with continuous infusion of midazolam 0,15-0,2 mg/kg/h and sufentanil 0,15-0,2 μg/kg/h. All our patients were curarized with cisatracurium 0,2-0,3 mg/kg/h to prevent shivering during TH and took anti-epileptic medication phenobarbital 10-15 mg/ kg two times a day to prevent infra-clinic convulsive seizure. Mild TH between 33 -34 °C was performed by active cooling with intravascular device (CoolGard® - Zoll, Chelmsford, UK) for 24 hours. Mean arterial pressure was maintained between \[75-80\] mmHg by titrated norepinephrine with or without inotropics (dobutamine, epinephrine) according cardiac output monitored by echocardiography. After 24 hours of hypothermia, warming was started at a rate of 0.2 ° C/hr; neuromuscular blocking agents were arrested at 35.5°C and sedation at 36.5°C. Neurological evaluation performed at 48 hours off sedation included a clinical evaluation (Glasgow score, myoclonus status, response to orders, motor response to stimulation, brain-stem reflexes). NSE was sampled between 48 and 72 H. EEGs were performed at Day-2, Day-3 and Day-5 off sedation and SEP at Day-5 off sedation. All EEGs were interpreted by two certified electroencephalographers blind from clinical neurologic outcome. Survival and neurologic outcome according to CPC were assessed at ICU discharge and three months later.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
400

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jun 2014

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2014

Completed
2.2 years until next milestone

First Submitted

Initial submission to the registry

July 26, 2016

Completed
1 month until next milestone

First Posted

Study publicly available on registry

September 1, 2016

Completed
3.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2019

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2019

Completed
Last Updated

September 1, 2016

Status Verified

July 1, 2016

Enrollment Period

5.3 years

First QC Date

July 26, 2016

Last Update Submit

August 26, 2016

Conditions

Keywords

Cardiorespiratory arrestNeurologic outcomeElectroencephalogramSomatosensory evoked potentialSynek classificationCerebral performance categoryHypothermia

Outcome Measures

Primary Outcomes (1)

  • comparison of electroencephalogram score to neurologic outcome evaluated by cerebral performance category

    Intensive care unit discharge

    J0 (date of inclusion)

Secondary Outcomes (1)

  • comparison of electroencephalogram score to neurologic outcome evaluated by cerebral performance category

    3 months

Study Arms (1)

patients

OTHER

Patient with cardiac arrest benefiting an electroencephalogram

Other: Electroencephalogram

Interventions

Prognostic evaluation of electroencephalogram score created with a retrospective cohort Creation of composite score to predict neurologic outcome in cardiorespiratory arrest

patients

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patient \> 18 years, hospitalized in resuscitation
  • Cardiac arrest in hospital or out
  • Collection of the written and informed consent

You may not qualify if:

  • Cardiorespiratory arrest concomitant with a neurological, traumatic or toxic pathology
  • History of cerebrovascular accident or cerebral anoxia
  • Patient whose family did not give an informed consent
  • Patient \< 18 years

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hôpital Lapeyronie - Département Anesthésie Réanimation A

Montpellier, 34295, France

RECRUITING

MeSH Terms

Conditions

Heart ArrestHypothermia

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular DiseasesBody Temperature ChangesSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Jean Paul ROUSTAN, MD, PhD

    Montpellier University Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Jean Paul ROUSTAN, MD, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 26, 2016

First Posted

September 1, 2016

Study Start

June 1, 2014

Primary Completion

October 1, 2019

Study Completion

December 1, 2019

Last Updated

September 1, 2016

Record last verified: 2016-07

Data Sharing

IPD Sharing
Will share

Locations